This research study is trying to determine which patients with newly diagnosed or
relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),
as grouped by their risk for tumor lysis syndrome (TLS), are able to safely tolerate an
accelerated, daily venetoclax dose ramp-up rather than the standard approved schedule (5-week
dose ramp-up).
The name of the study drug involved in this study is:
- Venetoclax
The following drugs may also be included in some participants treatment regimen:
- Obinutuzumab
- Rituximab